Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Shares Outstanding (2020 - 2025)

Historic Shares Outstanding for Janux Therapeutics (JANX) over the last 6 years, with Q3 2025 value amounting to $60.1 million.

  • Janux Therapeutics' Shares Outstanding rose 1487.73% to $60.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.1 million, marking a year-over-year increase of 1487.73%. This contributed to the annual value of $59.1 million for FY2024, which is 2770.05% up from last year.
  • Latest data reveals that Janux Therapeutics reported Shares Outstanding of $60.1 million as of Q3 2025, which was up 1487.73% from $59.3 million recorded in Q2 2025.
  • Over the past 5 years, Janux Therapeutics' Shares Outstanding peaked at $60.1 million during Q3 2025, and registered a low of $1.2 million during Q1 2021.
  • Its 5-year average for Shares Outstanding is $45.3 million, with a median of $41.9 million in 2023.
  • Its Shares Outstanding has fluctuated over the past 5 years, first skyrocketed by 438361.34% in 2021, then surged by 88.25% in 2023.
  • Janux Therapeutics' Shares Outstanding (Quarter) stood at $41.2 million in 2021, then grew by 0.9% to $41.6 million in 2022, then grew by 11.14% to $46.3 million in 2023, then increased by 27.7% to $59.1 million in 2024, then increased by 1.79% to $60.1 million in 2025.
  • Its Shares Outstanding was $60.1 million in Q3 2025, compared to $59.3 million in Q2 2025 and $59.2 million in Q1 2025.